Holen Sie sich die Stockscreener-App
3.6829
1.21%
-0.0471
Schlusskurs vom Vortag:
$3.73
Offen:
$3.8
24-Stunden-Volumen:
1.18M
Relative Volume:
0.37
Marktkapitalisierung:
$664.43M
Einnahmen:
$4.63M
Nettoeinkommen (Verlust:
$-201.14M
KGV:
-2.6802
EPS:
-1.3741
Netto-Cashflow:
$-167.10M
1W Leistung:
-8.10%
1M Leistung:
+11.67%
6M Leistung:
-9.46%
1J Leistung:
+114.24%
1-Tages-Spanne:
$3.63
$3.83
1-Wochen-Bereich:
$3.63
$4.40
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.68 | 673.46M | 4.63M | -201.14M | -167.10M | -1.3741 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.81 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Earnings Report: Is Prime Medicine Inc backed by strong institutional buyingWeekly Investment Report & Free Community Supported Trade Ideas - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Shares Gap UpHere's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Shares Down 6.9%Here's What Happened - MarketBeat
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway - Finviz
Will Prime Medicine Inc. stock outperform value stocksPrice Action & Technical Confirmation Alerts - Naître et grandir
Will Prime Medicine Inc. stock benefit from upcoming earnings reportsJuly 2025 Update & Growth Focused Entry Reports - Naître et grandir
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases - MSN
Guidance Update: Will Prime Medicine Inc stock hit new highs in YEARPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC - MarketBeat
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
Citizens reiterates Prime Medicine stock rating on PM359 pathway - Investing.com Australia
Citizens reiterates Prime Medicine stock rating on PM359 pathway By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives - simplywall.st
Prime Medicine unveils full year 2025 financial results and business update as progress advances - Traders Union
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline - TipRanks
Prime Medicine 2025 Net Loss Narrows as Revenue Rises -- Shares Fall Pre-Bell - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Total Revenue $4.6M, vs. FactSet Est of $5.7M - marketscreener.com
Prime Medicine : March 2026 Corporate Presentation - marketscreener.com
Prime Medicine 2025 net loss widens, hurt by higher R&D expenses - TradingView
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones - Stock Titan
PRME Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Prime Medicine, Inc. (PRME) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Investment Report: What is the target price for Prime Medicine Inc stockJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HighTower Advisors LLC Buys 312,401 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Stock Traders Buy Large Volume of Call Options on Prime Medicine (NYSE:PRME) - MarketBeat
Prime Medicine to Participate in Upcoming Investor Conferences - Bitget
Prime Medicine (NYSE:PRME) Trading 10.3% HigherStill a Buy? - MarketBeat
PRME (Prime Medicine) PB Ratio : 3.72 (As of Feb. 23, 2026) - GuruFocus
Prime Medicine (NASDAQ:PRME) Trading Up 1.2%Here's What Happened - MarketBeat
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company - Insider Monkey
Prime Medicine, Inc. $PRME Shares Acquired by Alphabet Inc. - MarketBeat
Aug Catalysts: Is Seacoast Banking Corporation of Florida impacted by rising rates2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Should I average down on Prime Medicine Inc. stockWeekly Investment Recap & Reliable Price Breakout Alerts - mfd.ru
Aug Analyst Calls: Is Prime Medicine Inc stock a smart retirement pick2025 Biggest Moves & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Earnings Miss: Will Prime Medicine Inc stock hit new highs in YEARJuly 2025 Spike Watch & AI Driven Price Forecasts - baoquankhu1.vn
Prime Medicine Advances Wilson Disease Pipeline With New Prescreening Study - TipRanks
Institutional Owners May Ignore Prime Medicine, Inc.'s (NASDAQ:PRME) Recent US$66m Market Cap Decline as Longer-term Profits Stay in the Green - 富途牛牛
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
What is the target price for Prime Medicine Inc. stockJuly 2025 Weekly Recap & Verified Trade Idea Suggestions - mfd.ru
Aug Selloffs: Should I average down on Prime Medicine Inc stockJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock - Yahoo Finance
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prime Medicine Inc-Aktie (PRME) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):